Takeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume – Here’s Why

Takeda Pharmaceutical Company Limited (NYSE:TAK) shares saw an uptick in trading volume on Wednesday . 853,714 shares changed hands during trading, a decline of 47% from the previous session’s volume of 1,609,208 shares.The stock last traded at $13.23 and had previously closed at $13.35.

Takeda Pharmaceutical Stock Performance

The firm has a fifty day moving average price of $13.51 and a 200 day moving average price of $13.89. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28. The stock has a market cap of $42.19 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51.

Institutional Trading of Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TAK. Millennium Management LLC lifted its position in Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after purchasing an additional 2,023,707 shares during the period. FMR LLC boosted its stake in shares of Takeda Pharmaceutical by 10.9% in the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after buying an additional 286,052 shares during the last quarter. Van ECK Associates Corp grew its holdings in Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after acquiring an additional 134,407 shares during the period. Managed Asset Portfolios LLC raised its position in Takeda Pharmaceutical by 0.3% during the third quarter. Managed Asset Portfolios LLC now owns 1,617,541 shares of the company’s stock valued at $23,001,000 after acquiring an additional 4,069 shares in the last quarter. Finally, Stifel Financial Corp lifted its holdings in Takeda Pharmaceutical by 103.9% in the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after acquiring an additional 224,594 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.